Last reviewed · How we verify
NCT04799691: STRATIC
Comparison of 2 Ventilatory Support Strategies During Coronavirus Disease 2019 (Covid-19) Pneumonia
trial testing Invasive ventilation strategy in COVID-19 in 133 participants. Completed in 15 January 2022.
15 January 2022
Quick facts
| Lead sponsor | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 133 |
| Start date | 1 February 2021 |
| Primary completion | 15 January 2022 |
| Estimated completion | 15 January 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Invasive ventilation strategy
- Non-invasive ventilation strategies
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective monocentric study compares 2 ventilatory support strategies on outcomes (length of stay, intubation, mortality) in patients admitted in Intensive Care Unit with Covid-19 related pneumonia : invasive strategy used during the first period and non-invasive strategies (Continuous Positive Airway Pressure, High Flow Nasal Canula, Prone Position) used during the second period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04799691
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer trials
Trials by the same sponsor.
- NCT07355582 — Injury Incidence, Severity and Burden in Elite Youth Rugby Players · recruiting
- NCT06865053 — Screening for Heart Failure in General Medicine Consultations · completed
- NCT06863246 — Postural Control in Chronic Obstructive Pulmonary Disease · completed
- NCT06871670 — Force Control in Chronic Obstructive Pulmonary Disease · completed
- NCT06857396 — Tracheal Exposure Without Tracheostomy Completion in Trans-oral Robotic Oncologic Surgery · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04799691 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
- Last refreshed: 12 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04799691.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing